Astria Therapeutics
ATXS
ATXS was delisted on the 22nd of January, 2026.
65 hedge funds and large institutions have $312M invested in Astria Therapeutics in 2023 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 28 increasing their positions, 11 reducing their positions, and 11 closing their positions.
168% more call options, than puts
Call options by funds: $316K | Put options by funds: $118K
155% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 11
36% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 11
7% more funds holding
Funds holding: 61 → 65 (+4)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
4% less capital invested
Capital invested by funds: $326M → $312M (-$14.2M)
46.87% less ownership
Funds ownership: 130.51% → 83.64% (-47%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.96M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$6.57M |
| 3 |
BlackRock
New York
|
+$2.66M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
+$2.63M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
+$2.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$8.79M |
| 2 |
TLP
Tri Locum Partners
New York
|
-$5.09M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.35M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.82M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.63M |
ATXS Hedge Fund Activity: Q1 2023 in Review
65 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q1 2023, worth a combined $312M — down 4.4% from $326M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new ATXS positions and 11 closed out — a net gain of 4 holders — while 28 added to existing stakes and 11 trimmed.
The largest buyer was Vanguard Group, adding an estimated $8.96M. The largest seller was Cormorant Asset Management, cutting an estimated $8.79M.
- 65 institutional investors held Astria Therapeutics (ATXS) as of Q1 2023, up from 61 in Q4 2022.
- Funds reported $312M of Astria Therapeutics stock for Q1 2023, down 4.4% quarter-over-quarter.
- 15 funds opened new Astria Therapeutics positions in Q1 2023 and 11 closed out, a net change of +4 holders.
- The largest Astria Therapeutics buyer in Q1 2023 was Vanguard Group, an estimated $8.96M added.
- The largest Astria Therapeutics seller in Q1 2023 was Cormorant Asset Management, an estimated $8.79M sold.
Based on aggregated 13F filings for Q1 2023.